General Inclusion Criteria	
Two face to face encounters with different	[DMCONFIRMED] = 1
dates of service in an outpatient setting or	(see Appendix A.1, A.2)
non-acute inpatient setting	AND
OR	the last day of the measurement period -
One face-to-face encounter in an acute	$[DATEOFBIRTH] \ge 18 \text{ and } \le 75$
inpatient or emergency department setting	
during the measurement period or the year	
prior to the measurement period (services	
that occur over both years may be counted)	
AND	
Patients who have a diagnosis of diabetes.	
(see Appendix A.1, A.2)	
AND	
Patient is $\geq 18$ and $\leq 75$ years of age the last	
day of the measurement period	

#### AND NOT

#### **General Exclusion Criteria**

Diabetes patients with a diagnosis of polycystic ovaries, gestational diabetes, and/or steroid induced diabetes who did not have any face-to-face visits during the measurement period (see Appendix B.1)

#### [DMCONFIRMED] = 3 (see Appendix B.1)

All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. ©2004 National Committee for Quality Assurance, all rights reserved.

- Measure Owner Designation
- ♣ AMA/PCPI is the measure owner
- ▲ CMS is the measure owner
- NCQA is the measure owner

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a "commercial use" refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain, (even if there is no actual charge for inclusion of the measure.)

These performance measure were developed and are owned by the National Committee for Quality Assurance ("NCQA"). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures.

NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA.

#### **DM Clinical Performance Measures**

HbA1c Management: Testing (<sup>\*</sup>DM-1): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had Hemoglobin A1c (HbA1c) testing

## Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

**Denominator Inclusions** 

All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)
	-

Denominator Exclusions

Diabetes patients meeting the general exclusion criteria (page 1)	Meeting exclusion criteria (page 1)

#### Numerator: One or more HbA1c test(s) performed during the measurement period

Patients who had one or more HbA1c tests performed during the measurement period (see Appendix C.1, C.2, C.3)	[DMHBA1CTEST] = 1 (see Appendix C.1, C.2, C.3)
---	---

HbA1c Management: Poor Control (<sup>\*</sup>DM-2): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had HbA1c in poor control (> 9.0%)

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

Denominator Inclusions	
All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)

Denominator Exclusions

Diabetes patients meeting the general	Meeting exclusion criteria (page 1)
exclusion criteria (page 1)	

## Numerator: The most recent HbA1c level (performed during the measurement period) is > 9.0% or is missing or was not done during the measurement period

Numerator Inclusions	
Patients with most recent HbA1c > $9.0\%$	[DMHBA1CTEST] = 1
during the measurement period or is	(see Appendix C.1, C.2, C.3)
missing or was not done during the	AND
measurement period	[DMHBA1CVALUE] > 9.0%
(see Appendix D.1)	(see Appendix D.1)
	OR
	[DMHBA1CTEST] = 1
	AND
	[DMHBA1CVALUE] = 0
	OR
	[DMHBA1CTEST] = 0

Blood Pressure Management (<sup>\*</sup>DM-3): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had a blood pressure < 140/80 mmHg

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

Denominator Inclusions

All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)

Denominator Exclusions	_
Diabetes patients meeting the general exclusion criteria (page 1)	Meeting exclusion criteria (page 1)

## Numerator: Patients with most recent systolic blood pressure measurement < 140 mm Hg *and* diastolic blood pressure < 80 mm Hg during the measurement period

Numerator Inclusions	
Patients with last systolic blood pressure	[DMBPMEASURE] = 1
measurement < 140 mm Hg and diastolic	AND
blood pressure < 80 mm Hg during the	[DMBPSYSTOLIC] < 140
measurement period	AND
(see Appendix E.1, E.2)	[DMBPDIASTOLIC] < 80
	(see Appendix E.1, E.2)

Lipid Management: Testing (<sup>®</sup>DM-4): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had LDL-C screening performed

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

Dene	omir	nato	or I	nclu	isions	
			/	-	•	

Each unique [PATIENTID] = one case in
the denominator
AND
Meeting inclusion criteria (page 1)

Denominator Exclusions

Diabetes patients meeting the general exclusion criteria (page 1)	Meeting exclusion criteria (page 1)

#### Numerator: An LDL-C test performed during the measurement period

Patient who had at least one LDL-C test performed during the measurement period (see Appendix F.1, F.2, F.3)	[DMLDLCTEST] = 1 (see Appendix F.1, F.2, F.3)
--	--

#### Lipid Management: Control < 100 mg/dL (<sup>\*</sup>DM-5): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had LDL-C testing < 100 mg/dL

# **Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes** (type 1 or type 2)

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator)	Each unique [PATIENTID] = one case in the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)

Denominator Exclusions

Diabetes patients meeting the general	Meeting exclusion criteria (page 1)
exclusion criteria (page 1)	

# Numerator: The most recent LDL-C level performed during the measurement period is < 100 mg/dL

Patients with most recent LDL-C level	[DMLDLCTEST] = 1
performed during the measurement period	(see Appendix F.1, F.2, F.3)
is < 100 mg/dL	AND
(see Appendix G.1)	[DMLDLCVALUE] < 100 mg/dL
	(see Appendix G.1)

Urine Protein Screening (<sup>\*</sup>DM-6): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had medical attention for nephropathy

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

**Denominator Inclusions** 

All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)

Denominator Exclusions

Diabetes patients meeting the general	Meeting exclusion criteria (page 1)
exclusion criteria (page 1)	

# Numerator: Patients who received any test for urine microalbumin, or had evidence of medical attention for nephropathy, or had a positive macroalbumin test, or received ACE Inhibitor/ARB therapy during the measurement period

[DMNEPHROPATHY] = 1
(see Appendix H.1, H.2, H.3, H.4, H.5 and
Tables 1, 2)

Eye Examination (<sup>\*</sup>DM-7): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had an eye exam (retinal) performed

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

Denominator Inclusions

All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)

Denominator Exclusions

Diabetes patients meeting the general	Meeting exclusion criteria (page 1)
exclusion criteria (page 1)	

## Numerator: Patients who received a retinal eye exam during the measurement period or a *negative* retinal eye exam during the year prior to the measurement period

_
[DMEYEEXAM] = 1
(see Appendix I.1, I.2, I.3, I.4)

Foot Examination (<sup>•</sup>DM-8): The percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament or pulse exam)

# Denominator: Patients 18 - 75 years of age who had a diagnosis of diabetes (type 1 or type 2)

Denominator Inclusions	
All patients (each unique patient identifier	Each unique [PATIENTID] = one case in
equals one case in the denominator)	the denominator
meeting the inclusion criteria (page 1)	AND
	Meeting inclusion criteria (page 1)
Denominator Exclusions	
Diabetes patients meeting the general	Meeting exclusion criteria (page 1)
exclusion criteria (page 1)	AND
Excluded for Medical Reasons:	[DMFOOTEXAM] = 3
• History of bilateral foot/leg	(see Appendix J.1)
amputation	

## Numerator: Patients who received a foot exam (visual inspection, sensory exam with monofilament or pulse exam) during the measurement period

Numerator Inclusions

(see Appendix J.1)

Patients who received a foot exam (at least	[DMFOOTEXAM] = 1
one of the three components) during the	(see Appendix K.1)
measurement period	
(see Appendix K.1)	